Next‐Generation Sequencing in Infectious‐Disease Diagnostics: Economic, Regulatory, and Clinical Pathways to Adoption
MicrobiologyOpen · 2025-12 · 14 (6)
DOI: 10.1002/mbo3.70104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MicrobiologyOpen, online erschienen am 26.11.2025. Verfasst von John Osei Sekyere. Beteiligte Einrichtung: Department of Medical Microbiology, School of Medicine, University of Pretoria, Pretoria, South Africa. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Communicable Diseases, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The author received no specific funding for this study..
Abstract (Originalsprache)
Next‐generation sequencing (NGS) has emerged as a transformative tool for infectious disease diagnosis, offering broad pathogen detection, antimicrobial resistance profiling, and syndromic panel testing. However, widespread clinical adoption remains hindered by insurance reimbursement challenges, high costs, and regulatory barriers. Unlike polymerase chain reaction (PCR), which enjoys well‐established Current Procedural Terminology (CPT) codes and reimbursement pathways, many NGS‐based tests lack standardized billing mechanisms, discouraging laboratories from integrating NGS into routine diagnostics. This article explores the economic, clinical, and technological considerations of targeted amplicon sequencing (tNGS) versus PCR and whole‐genome sequencing (WGS), demonstrating how optimized multiplexing strategies, emerging NGS platforms, and regulatory advancements can enhance feasibility. It is argued that insurance policies must evolve to recognize NGS's superior clinical utility in detecting polymicrobial infections, emerging pathogens, and antimicrobial resistance determinants, ultimately improving patient outcomes and reducing healthcare costs. Current reagent‐only costs now average US $65 per microbial genome, US $600 per 30× human genome, and US $130–600 per metagenomic sample when multiplexed; these figures continue to fall with higher multiplexing. To accelerate equitable adoption, we recommend near‐term payer coverage pilots for clearly defined clinical indications, dedicated CPT pathways for infectious‐disease sequencing (including metagenomic assays), and pragmatic validation frameworks that acknowledge genotype–phenotype limits while leveraging multiplexing and centralized reference workflows.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Microbiology, School of Medicine, University of Pretoria, Pretoria, South Africa.
- Institute of Biomarker Research and Department of Clinical Development, Medical Diagnostic Laboratories LLC, Hamilton Township, New Jersey, USA.
ORCID-Profile: John Osei Sekyere
Förderung
- The author received no specific funding for this study.
Zitieren
APA
Osei Sekyere, J. (2025). Next‐Generation Sequencing in Infectious‐Disease Diagnostics: Economic, Regulatory, and Clinical Pathways to Adoption. MicrobiologyOpen, 14(6). https://doi.org/10.1002/mbo3.70104
Vancouver
Osei Sekyere J. Next‐Generation Sequencing in Infectious‐Disease Diagnostics: Economic, Regulatory, and Clinical Pathways to Adoption. MicrobiologyOpen. 2025;14(6). doi:10.1002/mbo3.70104
BibTeX
@article{OseiSekyere2025,
author = {Osei Sekyere, John},
title = {Next‐Generation Sequencing in Infectious‐Disease Diagnostics: Economic, Regulatory, and Clinical Pathways to Adoption},
journal = {MicrobiologyOpen},
year = {2025},
volume = {14},
number = {6},
doi = {10.1002/mbo3.70104}
}
EUVIMED